Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX

Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System

(2017) Doug Coyle et al.   VALUE IN HEALTH

Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX

(2017) George P. Kim et al.   Expert Review of Clinical Pharmacology

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2016) Davendra P.S. Sohal et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer

(2016) Daniel A. Goldstein et al.   MEDICAL ONCOLOGY

Utilization and Cost of Supportive Care Among Patients Receiving Nab-Paclitaxel + Gemcitabine Versus Folfirinox for Metatstatic Pancreatic Cancer

(2016) M Patel et al.   VALUE IN HEALTH

Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer

(2016) Mahdi Gharaibeh et al.   JOURNAL OF MEDICAL ECONOMICS

Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

(2015) M Gharaibeh et al.   BRITISH JOURNAL OF CANCER

Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets

(2015) Francesco Sclafani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Treatment Patterns And Cost Of Care For Patients With Pancreatic Cancer

(2014) BS Seal et al.   VALUE IN HEALTH

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Costs and trends in pancreatic cancer treatment

(2012) Caitriona B. O'Neill et al.   CANCER

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE